ABSTRACT graft-versus-host disease (GVHD) is one of the main complications of hematopoietic stem cell transplantation, affecting about 50% to 80% of the patients. Acute GVHD and its clinical manifestations are discussed in this article, as well as the new NIH criteria for the diagnosis and classification of chronic GVHD. Therapy for both chronic and acute GVHD is an important field of discussion, as there is no proven superiority for the majority of therapies used after primary treatment has failed. Hence, this review is meant to be a useful consultation tool for hematologists dealing with this complex transplantation procedure complication
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host dis-ease (GVHD...
Introduction: Chronic graft-versus-host disease (chronic GVHD) is a leading cause of late death and ...
AbstractChronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allo...
Acute graft-versus-host disease (GVHD) is a severe complication that can arise after allogeneic hema...
Background: The use of non-myeloablative stem cell transplantation (NST) has recently been increasin...
Hematopoietic stem cell transplantation (HSCT) has become a standard treatment option in the managem...
Hematopoietic stem cell transplantation (SCT), which is being used increasingly day by day; is a tre...
Acute graft-versus-host disease (GVHD) is the most frequent, morbid complication following allogenei...
graft-versus-host disease (GVHD) is one of the main complications of hematopoietic stem cell transpl...
Historically, graft-versus-host disease (GVHD) beyond 100 days after hematopoi-etic cell transplanta...
AbstractChronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allo...
Graft-versus-host disease (GVHD) isan exaggerated immune response of the donor’s cells against the r...
Key Clinical Message Graft versus host disease (GVHD) is an immunologically mediated condition seen ...
Based on expert opinion and retrospective data the National Institutes of Health (NIH) Consensus Dev...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host dis-ease (GVHD...
Introduction: Chronic graft-versus-host disease (chronic GVHD) is a leading cause of late death and ...
AbstractChronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allo...
Acute graft-versus-host disease (GVHD) is a severe complication that can arise after allogeneic hema...
Background: The use of non-myeloablative stem cell transplantation (NST) has recently been increasin...
Hematopoietic stem cell transplantation (HSCT) has become a standard treatment option in the managem...
Hematopoietic stem cell transplantation (SCT), which is being used increasingly day by day; is a tre...
Acute graft-versus-host disease (GVHD) is the most frequent, morbid complication following allogenei...
graft-versus-host disease (GVHD) is one of the main complications of hematopoietic stem cell transpl...
Historically, graft-versus-host disease (GVHD) beyond 100 days after hematopoi-etic cell transplanta...
AbstractChronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allo...
Graft-versus-host disease (GVHD) isan exaggerated immune response of the donor’s cells against the r...
Key Clinical Message Graft versus host disease (GVHD) is an immunologically mediated condition seen ...
Based on expert opinion and retrospective data the National Institutes of Health (NIH) Consensus Dev...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host dis-ease (GVHD...
Introduction: Chronic graft-versus-host disease (chronic GVHD) is a leading cause of late death and ...